-
1 Comment
Jaguar Health, Inc is currently in a long term uptrend where the price is trading 6.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Jaguar Health, Inc's total revenue rose by 70.9% to $3M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-9K since the same quarter in the previous year.
Finally, its free cash flow grew by 457.1% to $11M since the same quarter in the previous year.
Based on the above factors, Jaguar Health, Inc gets an overall score of 5/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | NASDAQ |
ISIN | US47010C6075 |
CurrencyCode | USD |
PE Ratio | None |
---|---|
Target Price | 38 |
Market Cap | 5M |
Beta | 0.69 |
Dividend Yield | None |
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for JAGX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025